Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether motivational interviewing and skills building interventions reduce HIV risk behavior for adults with serious and persistent mental illness.


Clinical Trial Description

Our long-term objective is to reduce the incidence of HIV for people with serious and persistent mental illness (SMI) by developing an effective primary and secondary HIV risk reduction intervention for this population which can be easily delivered in the "real world" settings in which patients routinely receive care. Research findings document that the incidence of HIV infection, sexually transmitted diseases, and sexual and drug use behaviors are high among people with serious mental illness, as evidenced by rates of HIV infection and other sexually-transmitted diseases (STDs). A variety of factors underlie risky behaviors for the SMI, including cognitive impairment, poor judgment, affective instability and impulsiveness.

Skills-building (SB) HIV risk reduction interventions, typically delivered in a small group formats, have had modest success in increasing HIV-related knowledge and improving risk reduction skills for people with SMI, although these effects are transient. As skills-building interventions are currently the standard of care in most research and clinical settings for HIV prevention, it is important to identify new ways to augment these interventions.

A relatively new and promising addition to the armamentarium of individualized interventions is Motivational Interviewing (MI). MI is an approach designed to reduce ambivalence and enhance intrinsic motivation to change problematic behaviors. Previous researchers have noted effects for both SB and MI interventions independently, however, these effects tend to be fairly modest. Integrating these approaches in a systematized way allows us to test the degree to which this combination is useful, given that both motivation and skills are clearly important in effecting health behavior change.

Our specific primary aims are the following:

1. To adapt SB and MI interventions for HIV risk reduction for men and women with serious and persistent mental illness (SMI).

Interventions for HIV risk reduction for people with SMI are typically offered in a group format and focus primarily on skills-building. We have developed and refined a brief, individually-tailored skills-building intervention (SB Intervention), based on these existing manuals. We have also adapted and refined a brief individually-tailored Motivational Interviewing intervention to target HIV risk behaviors, incorporating skills-building techniques analogous to those in the SB intervention, resulting in a Motivational-Interviewing & Skills-Building Intervention (SB-MI Intervention). Adaptation and refinement of the SB and SB-MI interventions was informed by consulting with experts in MI, SMI, and HIV risk reduction, eliciting feedback from advisory boards of providers and consumers, and conducting feedback interviews with participants who have completed participation in the study.

2. To pilot test and obtain preliminary data with regard to the feasibility of our interventions and the differences in outcome associated with our SB and SB-MI interventions for reduction of HIV-related risk behaviors in a cohort of SMI adults.

Comparison of SB and SB-MI interventions in the proposed pilot study will allow us to assess the degree to which incorporation of motivational techniques are helpful in augmenting skills-building interventions for HIV risk reduction for people with SMI. These preliminary analyses will inform our need to refine the adapted interventions (SB and SB-MI).

3. To offer HIV counseling and testing for at-risk individuals with SMI, with an emphasis on connecting participants to appropriate medical and mental health services.

To date, increasing rates of HIV counseling and testing for the SMI has not been a primary focus of clinical research, which we believe to be a significant public health deficit. As part of both of our interventions we are providing information about HIV counseling and testing services to those participants not identified as HIV-seropositive and encouraging them to access these services. We are then tracking the degree to which participants follow up on these referrals as part of our follow-up evaluations. This will allow us to test the degree to which our interventions are helpful in increasing rates of HIV testing.

4. To begin to explore the relationships between participant characteristics, HIV risk behaviors, and response to our interventions.

One of the unique features of our intervention is that it assumes an individually-tailored approach, which can address unique patient characteristics inherent in a heterogeneous sample. Indeed, using a heterogeneous sample greatly facilitates our primary long-term objective, which is to develop useable interventions that can be adapted in real-world settings. This project will allow us to begin to identify those characteristics that are likely to be associated with more positive outcomes (i.e. greater risk reduction, increased rates of HIV testing). ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00643305
Study type Interventional
Source Boston Medical Center
Contact
Status Completed
Phase Phase 2
Start date February 2006
Completion date January 2009

See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2